RET Lung
Showing 1 - 25 of >10,000
Nonsmall Cell Lung Cancer Trial in Shanghai (HS-10365 capsules)
Recruiting
- Nonsmall Cell Lung Cancer
- HS-10365 capsules
-
Shanghai, Shanghai, ChinaShanghai Chest Hospital
Nov 22, 2023
NSCLC Trial in Shanghai (SY-5007)
Recruiting
- Non-Small Cell Lung Cancer
-
Shanghai, Shanghai, ChinaShanghai Pulmonary Hospital
Sep 4, 2023
RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer Trial in Chang chun
Not yet recruiting
- RET-altered Non Small Cell Lung Cancer
- +3 more
-
Chang chun, Jilin, ChinaJinlin Province Cancer Hosipital
Dec 21, 2022
NSCLC, Thyroid Tumors Trial (LOXO-260)
Temporarily not available
- Carcinoma, Non-Small-Cell Lung
- Thyroid Neoplasms
- (no location specified)
Sep 20, 2022
Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial in Tampa
Recruiting
- Lung Non-Small Cell Carcinoma
- +4 more
- Carboplatin
- +2 more
-
Tampa, FloridaMoffitt Cancer Center
Aug 16, 2022
Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion
Recruiting
- Non-small Cell Lung Cancer
-
Changsha, Hunan, ChinaYongchang Zhang
Mar 1, 2022
ALK-positive NSCLC (NSCLC), RET-positive NSCLC (NSCLC), RET-positive Thyroid Cancer Trial in Irvine, Boston (Alectinib)
Terminated
- ALK-positive Non-small Cell Lung Cancer (NSCLC)
- +2 more
-
Irvine, California
- +3 more
Aug 30, 2021
NSCLC Trial in Guangzhou (HA121-28 tablet)
Recruiting
- NSCLC
- HA121-28 tablet
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Centre
Aug 2, 2022
Lung Cancer, Non Small Cell Lung Cancer Trial in Aurora (Amivantamab 1050mg, Amivantamab 1400mg, Amivantamab (to be determined))
Not yet recruiting
- Lung Cancer
- Non Small Cell Lung Cancer
- Amivantamab 1050mg
- +2 more
-
Aurora, Colorado
- +2 more
Apr 25, 2023
RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer Trial in Worldwide
Active, not recruiting
- RET-altered Non Small Cell Lung Cancer
- +39 more
- pralsetinib (BLU-667)
-
Phoenix, Arizona
- +65 more
Nov 10, 2022
NSCLC, RET Driver Mutation, BRAF V600 Mutation Trial in Guanzhou (Toripalimab, Nab paclitaxel, Pemetrexed)
Recruiting
- Non-Small Cell Lung Cancer
- +5 more
- Toripalimab
- +3 more
-
Guanzhou, Guangdong, ChinaGuangdong Lung Cancer Institute, Guangdong Provincial People's H
Apr 4, 2023
Pralsetinib to Best Available Therapy in RET-Fusion Positive
Enrolling by invitation
- RET-fusion Non Small Cell Lung Cancer
- +16 more
-
New York, New York
- +2 more
Aug 9, 2021
Advanced Nonhaematologic Malignancies Trial in Worldwide (BOS172738)
Active, not recruiting
- Advanced Nonhaematologic Malignancies
-
Philadelphia, Pennsylvania
- +20 more
Sep 23, 2022
NSCLC, Medullary Thyroid Cancer, Solid Tumor Trial in Shanghai, Tianjin (SY-5007)
Recruiting
- Non-Small Cell Lung Cancer
- +2 more
-
Shanghai, Shanghai, China
- +1 more
Mar 17, 2022
Non Small Cell Lung Cancer, Ovarian Cancer, RET Gene Mutation Trial in New York (RXDX-105)
Completed
- Non Small Cell Lung Cancer
- +3 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center 1275 York Avenue
Sep 30, 2020
NSCLC Trial in Worldwide (Selpercatinib, Carboplatin, Cisplatin)
Active, not recruiting
- Non-Small Cell Lung Cancer
- Selpercatinib
- +4 more
-
Berazategui, Buenos Aires, Argentina
- +195 more
Jan 30, 2023
Solid Tumor, Medullary Thyroid Cancer Trial in China (Selpercatinib)
Active, not recruiting
- Solid Tumor
- Medullary Thyroid Cancer
-
Guangzhou, Guangdong, China
- +12 more
May 9, 2022
Advanced Solid Tumor Trial in Chengdu (KL590586 Capsule)
Enrolling by invitation
- Advanced Solid Tumor
- KL590586 Capsule
-
Chengdu, Sichuan, ChinaSichuan Kelun Botai Biopharmaceutical Co.
Feb 23, 2022